1 month ago
12
David Jagielski, CPA, The Motley Fool
Tue, July 14, 2026 astatine 7:20 AM CDT 4 min read
When a institution acquires different business, there's often going to beryllium a premium involved, particularly if it's successful bully signifier oregon has immoderate promising assets successful its portfolio. But normally, you don't spot a institution wage double what its existent valuation is.
That's what Vertex Pharmaceuticals (NASDAQ: VRTX) precocious did erstwhile it announced a $10 cardinal acquisition of Crinetics Pharmaceuticals (NASDAQ: CRNX), a institution that specializes successful endocrine disorders and diseases. Vertex agreed to wage a 102% premium for the stock, somewhat much than treble its valuation. While it was large quality for Crinetics investors, it didn't beryllium each that good with Vertex investors, and the banal proceeded to autumn sharply connected the news.
Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »
Why did Vertex wage truthful overmuch for the healthcare company?
Management was "floored" by this 1 cause
Vertex expects the assets it gets from Crinetics to adhd arsenic overmuch arsenic $5 cardinal successful revenue. And what truly stood retired to absorption was a peculiarly charismatic drug: atumelnant. The cause isn't approved yet, but Vertex executives were thrilled with its advancement successful objective trials arsenic a attraction for congenital adrenal hyperplasia (CAH).
Atumelnant is simply a once-daily pill that has been well-tolerated successful trials without superior adverse events and which helped bring patients' hormone levels backmost down to adjacent mean levels. It has the imaginable to beryllium a starring therapy for CAH, assuming it obtains approval.
"When we saw that data, we were floored. That is very, precise important to this field."
"We are besides excited by the important imaginable of atumelnant to alteration the attraction scenery for CAH, mounting a caller modular of attraction wherever patients bash not person to take betwixt managing their excess adrenal androgens and enduring the broadside effects of high-dose steroids."
- Dr. Reshma Kewalramani, Vertex CEO
Vertex remains a apical maturation banal to ain
The precocious terms tag that Vertex paid for Crinetics banal whitethorn person alarmed investors, arsenic shares of Vertex fell sharply connected the news. Prior to the announcement connected July 6, the banal was trading adjacent its 52-week precocious astatine astir $530, but would extremity up falling to conscionable implicit $485 arsenic of the extremity of past week. While it's not a immense sell-off, it does bespeak that investors had a spot of archetypal apprehension erstwhile it was announced.
.png)
English (CA) · 
English (US) · 
Spanish (MX) ·